Experimental CAR-T therapy targets Hard-to-Treat HER2 cancers

NCT ID NCT07593820

Recruiting now Disease control Sponsor: Vall d'Hebron Institute of Oncology Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing a new type of cell therapy called p95HER2.CAR-TECH2Me for people with advanced HER2-positive breast, gastric, or endometrial cancers that have spread. The treatment uses a patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. About 15 participants will receive a single infusion after a short course of chemotherapy, and researchers will closely monitor safety and any signs of tumor shrinkage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: p95HER2.CAR-TECH2Me cells (a type of immune cell therapy made from the patient's own blood)
What this could lead to: If it works, this could point toward a new treatment option for advanced HER2-positive cancers that have not responded to other therapies.
What could go wrong: This is a very early Phase 1 trial with only 15 people, focused mainly on safety. The treatment may not shrink tumors, and there are risks of serious side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER METASTATIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm endometrial carcinoma gastric cancer gastric carcinoma gastric neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ENDOMETRIAL CANCER METASTATIC METASTATIC BREAST CANCER METASTATIC GASTRIC CANCER

Contacts and locations

Locations

Hospital Del Mar
NOT_YET_RECRUITING

Barcelona, Catalonia, 08003, Spain
Hospital Universitari Vall D Hebron
RECRUITING

Barcelona, Catalonia, 08035, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.